EXPLEOSOL.NS(EXPLEOSOL.NS)
EXPLEOSOL.NS
No analyst ratings available
No analyst price targets available for EXPLEOSOL.NS
Analyst coverage may not be available for this symbol
Earnings surprise history unavailable.
No recent analyst actions
| Metric | Q3 2026 | Q4 2026 | Q2 2027 | Q3 2027 | Q4 2027 | Q2 2028 | Q3 2028 | Q4 2028 |
|---|---|---|---|---|---|---|---|---|
| Revenue Avg | $970M | $970M | $1.20B | $1.20B | $1.36B | $2.38B | $2.38B | $2.33B |
| Low | $970M | $970M | $1.20B | $1.20B | $1.36B | $2.38B | $2.38B | $2.33B |
| High | $970M | $970M | $1.20B | $1.20B | $1.36B | $2.38B | $2.38B | $2.33B |
| EBITDA Avg | $180M | $180M | $222M | $222M | $252M | $441M | $441M | $432M |
| Low | $180M | $180M | $222M | $222M | $252M | $441M | $441M | $432M |
| High | $180M | $180M | $222M | $222M | $252M | $441M | $441M | $432M |
| EBIT Avg | $150M | $150M | $185M | $185M | $210M | $367M | $367M | $359M |
| Low | $150M | $150M | $185M | $185M | $210M | $367M | $367M | $359M |
| High | $150M | $150M | $185M | $185M | $210M | $367M | $367M | $359M |
| Net Income Avg | — | — | — | — | — | — | — | — |
| Low | — | — | — | — | — | — | — | — |
| High | — | — | — | — | — | — | — | — |
| EPS Avg | — | — | — | — | — | — | — | — |
| Low | — | — | — | — | — | — | — | — |
| High | — | — | — | — | — | — | — | — |
| Analysts (Rev / EPS) | 1 / — | 1 / — | 1 / — | 1 / — | 1 / — | 1 / — | 1 / — | 1 / — |